Multicenter Real-World Experience from the Turkish Oncology Group: Sotorasib in KRAS G12C-Mutated NSCLC
Orhun Akdogan1, Osman Sutcuoglu1, Didem Tunali2, Didem Divrikoglu3, Ali Fuat Gurbuz4, Yasin Kutlu31Department of Medical Oncology, Gazi University, Ankara, Türkiye, 2Department of Medical Oncology, Koç University , İstanbul, Türkiye, 3Department of Medical Oncology, Trakya University, Edirne, Türkiye, 4Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Türkiye
Objectives: Non-small cell lung cancer (NSCLC) is a common and aggressive type of lung cancer, with KRAS p.G12C mutations found in approximately 13% of cases. Sotorasib, a KRAS G12C inhibitor, has shown promise in clinical trials, but real-world data is limited. This study aims to evaluate the real-world efficacy and safety of sotorasib in Turkish patients with KRAS p.G12C-mutated NSCLC. Methods: A multicenter retrospective cohort study was conducted across 15 centers in Turkey, including 41 patients treated with sotorasib between August 2020 and May 2023. Data were collected from electronic hospital databases and included patient demographics, treatment details, and outcomes. The primary endpoints were overall survival (OS), progression-free survival (PFS), and treatment response. Secondary endpoints included treatment-related adverse effects (TRAEs). Results: Among the 41 patients, the median age was 64.5 years, with 78% being male and 93% having adenocarcinoma. Sotorasib was used as first-line treatment in 39% of patients. The overall response rate (ORR) was 34.2%, with a median PFS of 8.3 months and a median OS of 15.8 months. TRAEs were reported in 48.7% of patients, with grade 3-4 events in 12.2%, primarily diarrhea and liver enzyme elevations. No treatment-related deaths occurred. Conclusion: This real-world study confirms the efficacy and safety of sotorasib in treating KRAS p.G12C-mutated NSCLC, with outcomes consistent with clinical trial data. Sotorasib provides a valuable treatment option for this patient population, although further research is needed to optimize patient selection and management strategies. Keywords: Non-small cell lung cancer (NSCLC), KRAS p.G12C mutation ,Sotorasib, Real-world study, Treatment efficacy, Safety profile
Cite This Article
Akdogan O, Sutcuoglu O, Tunali D, Divrikoglu D, Gurbuz A, Kutlu Y. Multicenter Real-World Experience from the Turkish Oncology Group: Sotorasib in KRAS G12C-Mutated NSCLC. EJMI. 2024; 8(4): 274-279
Corresponding Author: Orhun Akdogan